Danish drugmaker Novo Nordisk, the creator of Ozempic and Wegovy, announced a shocking statistic Thursday: Over 25,000 people begin Wegovy each week. The number is five times larger than the numbers from December—about 5,000 new users a week. The company went on to boast a 22% sales increase in its first-quarter earnings report Thursday, outperforming analysts’ expectations and bringing in about $9.4 billion in net sales. Sales of Ozempic rose 42%, while Wegovy’s skyrocketed 106%. Novo... Read this story
